Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human fibrinogen + human thrombin (OMRIX Biopharmaceuticals, Inc.)
- Development stage
- Unknown
- Lead developer
- OMRIX Biopharmaceuticals
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Topical
01
Overview
Ivisel (marketed globally as Evicel) is a human plasma-derived fibrin sealant consisting of two active components: human clottable protein (predominantly fibrinogen) and human thrombin. Developed by Omrix Biopharmaceuticals (a subsidiary of Johnson & Johnson's Ethicon), it is designed to mimic the final stages of the physiological coagulation cascade. Upon mixing during topical application, thrombin cleaves fibrinogen into fibrin monomers, which polymerize to form a stable fibrin clot that promotes hemostasis and tissue sealing. Unlike earlier-generation fibrin sealants, Ivisel is free of synthetic or bovine-derived aprotinin and tranexamic acid, reducing the risk of hypersensitivity and neurotoxicity. It is approved as an adjunct to hemostasis in various surgical settings, including vascular surgery and dura mater closure, and is under clinical investigation for sutureless urethrovesical anastomosis in radical prostatectomy.
- Brand names
- EvicelIviselIvysel
- Other names
- fibrin gluefibrin sealant (human)fibrinogen + thrombinИвисел
02
Targets
FXIIIa (Coagulation factor XIII A subunit)FGA (Fibrinogen alpha chain)FGB (Fibrinogen beta chain)FGG (Fibrinogen gamma chain)ITGA2B (Integrin alpha-IIb)ITGB3 (Integrin beta-3)F2R (Protease-activated receptor 1)PAR4 (Protease-activated receptor 4)
Beyond the preview
Go deeper on human fibrinogen + human thrombin (OMRIX Biopharmaceuticals, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human fibrinogen + human thrombin (OMRIX Biopharmaceuticals, Inc.).